Acitretin

證據等級: L5

預測適應症: 4 個

Acitretin: From Psoriasis to Acne

One-Sentence Summary

Acitretin is a second-generation oral retinoid with an established international role in treating severe psoriasis and hyperkeratotic skin disorders, though it does not currently hold MHRA authorisation within the available dataset. The TxGNN model predicts it may be effective for acne (disease) — encompassing both acne vulgaris and hidradenitis suppurativa (acne inversa) — with 1 registered clinical trial (of limited direct relevance) and 18 publications identified in support of this direction. The majority of the retrieved evidence, however, pertains to the related compound isotretinoin rather than acitretin specifically, and should be interpreted with caution.

Quick Overview

Item	Content
Original Indication	Psoriasis (established international indication; no MHRA authorisation identified in the current dataset)
Predicted New Indication	Acne (disease)
TxGNN Prediction Score	99.94%
Evidence Level	L4
UK Market Status	Not licensed (per available data)
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, formal mechanism of action data was not retrieved via the DrugBank query included in this Evidence Pack. Based on known pharmacological information, however, acitretin belongs to the aromatic retinoid class — second-generation synthetic analogues of vitamin A — and exerts its effects primarily through activation of nuclear retinoic acid receptors RAR-α and RAR-γ. This receptor activation drives normalisation of epidermal differentiation, suppression of sebaceous gland hyper-secretion, correction of follicular hyperkeratinisation, and downregulation of pro-inflammatory cytokines including IL-1β and TNF-α.

The connection to acne is mechanistically direct. The pathogenesis of acne vulgaris involves three converging drivers — excessive sebum production, abnormal follicular keratinisation, and Cutibacterium acnes-mediated inflammation — all of which sit within the pharmacological scope of retinoid action. This mechanistic overlap is even more compelling for hidradenitis suppurativa (HS, also termed acne inversa), where follicular occlusion and deep-seated dermal inflammation are the central pathological processes; retinoid-mediated keratinocyte normalisation may be particularly well suited to interrupting this cycle.

It is important to contextualise acitretin’s positioning: isotretinoin, a first-generation retinoid with a distinct molecular structure, already occupies the standard-of-care role for severe acne vulgaris. Acitretin’s differentiated clinical value likely lies in HS, in patients not suitable for isotretinoin, or potentially as maintenance therapy. Multiple published case reports and a European S1-level clinical guideline already reference acitretin as a treatment option for HS, providing an additional layer of plausibility to the TxGNN prediction and suggesting that the model has correctly identified a biologically grounded signal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT04663906	N/A	Unknown	300	Study drug is isotretinoin, not acitretin. Investigates whether retinoid-induced nasal mucosal dryness increases risk of COVID-19 infection or complications. Not relevant to acitretin’s efficacy in acne.

Interpretation note: No registered clinical trials specifically evaluating acitretin for acne (vulgaris or inversa) were identified at the time of data collection (26 March 2026). The single retrieved trial concerns a different retinoid (isotretinoin) and addresses a COVID-19 safety question; it does not constitute evidence for the repurposing hypothesis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
20874789	2011	Long-term case series	British Journal of Dermatology	Long-term outcomes of acitretin therapy for HS over 25 years; provides the most directly relevant clinical evidence for acitretin in acne-related pathology in this pack
12080949	2002	Case Report	Cutis	Severe nodulocystic acne and HS treated with acitretin following two failed isotretinoin courses; improvement noted, illustrating acitretin as a rescue option
25640693	2015	Clinical Guideline (S1)	Journal of the European Academy of Dermatology and Venereology	European S1 guideline for HS/acne inversa; summarises clinical evidence and treatment pathways including retinoid use
41692081	2026	Review	Clinics in Dermatology	Recent comprehensive review of vitamin A and retinoids in dermatology; acitretin listed among the oral retinoids used therapeutically alongside isotretinoin and alitretinoin
29234829	2018	Narrative Review	Der Hautarzt	Drug therapy options for acne inversa; acitretin placed within the broader treatment landscape alongside antibiotics and TNF-α inhibitors, noting the limited evidence base
8573927	1995	Mechanistic Review	Dermatology	Examines retinoid inhibition of sebaceous gland activity; discusses whether anti-acne effects of newer oral retinoids (including acitretin) can be predicted from experimental models
9074840	1997	Review	Drugs	Broad review of retinoid use in dermatology covering acitretin’s role in psoriasis, hyperkeratotic disorders, severe acne-related conditions, and chemoprevention of skin malignancy
2112772	1990	Mechanistic (laboratory)	Prostaglandins	Demonstrates acitretin inhibits eosinophil LTC4 (leukotriene C4) production; supports an anti-inflammatory mechanism relevant to acne pathophysiology
1617858	1992	Review (PK/PD)	Clinical Pharmacokinetics	Pharmacokinetic and efficacy profile of acitretin and related retinoids; contextualises acitretin’s position relative to isotretinoin in the treatment of skin diseases
28476075	2017	Cochrane Review	Cochrane Database of Systematic Reviews	Cochrane review of pharmacological treatments for discoid lupus erythematosus; includes retinoids and provides context for acitretin’s broader immunomodulatory role in inflammatory skin conditions

UK Market Information

No MHRA marketing authorisations for acitretin were identified in the dataset used for this Evidence Pack (recorded market status: not licensed; 0 authorisations). Clinicians should verify the current licensing position directly against the MHRA Product Licence register and the British National Formulary, as acitretin products (e.g., Neotigason) may be available in the UK under existing authorisations not captured by this query.

Any prescribing of acitretin for acne (vulgaris or inversa) would constitute off-label use and would require appropriate clinical governance, documented informed consent, and adherence to local and national prescribing frameworks.

Safety Considerations

Detailed warnings, contraindications, and drug interaction data were not available in this Evidence Pack. The following high-priority safety signals are drawn from the mechanistic rationale and the known retinoid class profile:

Teratogenicity (critical): Acitretin is a Pregnancy Category X agent under international classifications, with robust evidence of teratogenicity in both animal models and humans. Women of childbearing potential must be enrolled in a formal pregnancy prevention programme, and the required contraception-free period after stopping treatment is substantially longer than for isotretinoin due to acitretin’s conversion to etretinate.
Paediatric bone toxicity: Long-term systemic retinoid use in children carries a recognised risk of growth plate effects and skeletal changes; this is a particular concern for any consideration of off-label use in younger patients.

Please refer to the SmPC and the BNF for the complete safety profile, including requirements for liver function and fasting lipid monitoring, and for full contraindications and drug interaction information. Suspected adverse reactions should be reported via the Yellow Card Scheme (https://yellowcard.mhra.gov.uk/).

Conclusion and Next Steps

Decision: Hold

Rationale: The biological rationale linking acitretin to acne is mechanistically credible, and there are scattered case reports and guideline references that provide a limited initial signal, particularly for hidradenitis suppurativa. However, no dedicated clinical trials for acitretin in acne have been identified, the retrieved literature is predominantly indirect (concerning isotretinoin), and the current evidence level of L4 (mechanistic and preclinical) is insufficient to support a repurposing decision at this stage. The absence of UK licensing data also requires resolution before any further development steps are taken.

To proceed, the following is needed:

Dedicated acitretin literature review: Commission a targeted systematic review of acitretin (as opposed to isotretinoin or etretinate) specifically for acne vulgaris and hidradenitis suppurativa, including grey literature, conference abstracts, and unpublished case series
Mechanism of action confirmation: Retrieve the formal DrugBank receptor-binding and pharmacodynamic profile for acitretin to document the RAR-α/γ pathway and distinguish it from isotretinoin’s receptor selectivity
Full safety data retrieval: Obtain SmPC warnings, contraindications, and DDI data from the MHRA register; document the pregnancy prevention programme requirements
UK regulatory status verification: Confirm the MHRA licensing position for acitretin directly against the live register to clarify whether any authorisation already exists
Clinical positioning analysis: Define the specific patient subpopulation (e.g., isotretinoin-intolerant patients, moderate-to-severe HS) where acitretin offers the clearest differentiation from existing therapies
Prospective study design: If the above steps yield a compelling enough signal, develop a pilot or Phase 2 RCT protocol for acitretin in moderate-to-severe HS, where the mechanistic rationale is strongest and the unmet clinical need is highest
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.